Trading Update
IXICO plc anticipates its revenue for the year ending 30 September 2026 to be at least £8.0 million, exceeding previous market expectations and representing approximately 22% growth compared to FY 2025. This upward revision from the prior forecast of £7.5 million, which represented a 15% increase, is attributed to strong trading performance driven by a diverse client base and contract extensions.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
07 July 2026: IXICO plc (AIM: IXI), IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, today provides a trading update for its current year which ends on 30 September 2026 ("FY 2026").
The Company anticipates FY 2026 revenues to be at least £8.0 million, ahead of existing market expectations and representing an increase of c.22% on FY 2025 revenues. This update, a consequence of strong trading across an increasingly diverse client base combined with contract extensions, replaces the original forecast of £7.5 million, previously representing a 15% uplift on FY25 revenues.
Bram Goorden, CEO of IXICO, said: "The strong performance has been driven by a continued uplift in contract wins, contract extensions, and revenue diversification. The results are a direct result of a plan put in place in 2024 and clearly demonstrating the fruits of that strategy as it matures. We will continue to deliver innovative differentiated scientific products, services and technology that position IXICO at the forefront of neuroscience."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.